Latest news
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - TradingViewTradingView · Fri, 07 Aug 2026 22:20:49 GMTHalozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know - TradingViewTradingView · Fri, 07 Aug 2026 21:35:42 GMTHalozyme Therapeutics, Inc. Stock 12‑Month Price Target Raised to $99.56, Implies 16% Upside - TradingViewTradingView · Fri, 07 Aug 2026 21:20:19 GMTThese Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months - TradingViewTradingView · Fri, 07 Aug 2026 17:55:37 GMTHalozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up - TradingViewTradingView · Fri, 07 Aug 2026 17:35:00 GMTHalozyme Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:37:34 GMTHALOZYME THERAPEUTICS, INC. 2026: Revenue $481M, EPS $1.9— 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMTHalozyme Reports Q2 2026: Revenue $481M, Royalties $308M, Raises 2026 Guidance - TradingViewTradingView · Thu, 06 Aug 2026 20:13:04 GMT